title: Alzheimer disease in 2020.
abstract: Remarkable advances in unraveling the biological underpinnings of Alzheimer disease (AD) have occurred during the last 25 years. Despite this, we have made only the smallest of dents in the development of truly disease-modifying treatments. What will change over the next 10 years? While the answer is not clear, we make several predictions on the state of the field in 2020, based on the rich knowledge described in the other contributions in this collection. As such, our predictions represent some of the principal unresolved questions that we believe deserve special investigative attention in the coming decade.
authors.affiliation: Department of Neurology, Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri 63110, USA. holtzman@neuro.wustl.edu
authors.forename: David M
authors.initials: DM
authors.lastname: Holtzman
authors.forename: Eckhard
authors.initials: E
authors.lastname: Mandelkow
authors.forename: Dennis J
authors.initials: DJ
authors.lastname: Selkoe
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism*; D016229:Amyloid beta-Peptides / Q000378:metabolism; D002450:Cell Communication; D002986:Clinical Trials as Topic; D006801:Humans; D016875:tau Proteins / Q000378:metabolism
chemical_list: D016229:Amyloid beta-Peptides; D016875:tau Proteins